Comprehensive 2026 Study Confirms Standard Antidepressant Doses During Pregnancy Pose No Significant Risk to Infant Health

A new study in The Lancet finds standard antidepressant doses are safe during pregnancy, showing no link to birth defects or developmental issues in infants.

By: AXL Media

Published: Feb 24, 2026, 8:37 AM EST

Source: The information in this article was sourced from News Medical

Statistical Clarity for Maternal Mental Health

The clinical dilemma of whether to continue antidepressant medication during pregnancy has long been a source of anxiety for expectant mothers and healthcare providers alike. According to a landmark study led by the University of Oslo and published in February 2026, standard therapeutic doses of common antidepressants do not appear to increase the risk of major congenital malformations or developmental delays. By analyzing health data from over 1.5 million pregnancies across several nations, the researchers provided the most robust evidence to date that the benefits of maintaining maternal mental stability may outweigh the potential risks of medication exposure.

Evaluating the Safety of SSRI Class Medications

The research focused primarily on selective serotonin reuptake inhibitors (SSRIs), which are the most frequently prescribed class of antidepressants for pregnant individuals. According to the findings, infants exposed to these medications in utero showed no higher incidence of heart defects or nervous system abnormalities compared to those in the control group. The study specifically adjusted for the mother’s underlying mental health condition, ensuring that the results reflected the impact of the drug itself rather than the stress of untreated depression, which in itself can negatively affect fetal health.

Debunking Concerns Over Developmental Milestones

Previous smaller studies had suggested potential links between antidepressant use and conditions such as autism or ADHD in children. However, this 2026 analysis utilized a sibling-comparison design, which allowed researchers to compare children born to the same mother—some exposed to antidepressants and others not. According to the study authors, when genetic and environmental factors were held constant, there was no measurable difference in neurodevelopmental outcomes. This suggests that earlier concerns may have been influenced by confounding variables rather than the medication.